Drug Class: DMARDs, Janus Kinase (JAK) inhibitors
Brand Names: Rinvoq


15 mg tablet (extended release) once a day

Potential Side Effects

The most common side effects are upper respiratory tract infections, nausea and cough.

Based on a safety trial of the JAK inhibitor tofacitinib (Xeljanz), the FDA has determined upadacitinib and other JAK inhibitors have an increased risk of serious cardiovascular-related events, including heart attack and stroke; cancer, including lymphoma and lung cancer; thrombosis and death.

Special Instructions

Swallow whole. Do not cut, chew, crush, divide or dissolve.

Blood test are required before and during treatment.

Patients should be tested and treated for tuberculosis (TB) before and during use of this drug.

Be Aware

Increased risk of serious viral, invasive fungal and bacterial infections (such as tuberculosis), malignancies (including lymphoma), thrombosis (including deep vein thrombosis and pulmonary embolism) and herpes zoster (shingles).

Do not use if pregnant, planning to become pregnant or breastfeeding. 

Do not get live, attenuated vaccines while on this medication. 



                                                                                 LAST UPDATED: 09/18/2021

The Arthritis Today Drug Guide is meant for education – not self-medicating. Arthritis Today, the Arthritis Foundation and the Drug Guide Medical Review Panel do not endorse any products mentioned in this guide. While we endeavor to keep the information up to date, we make no representations or warranties about the completeness of the information provided.